Pharmala Biotech Holdings (XCNQ:MDMA) EV-to-EBIT : -65.64 (As of May. 04, 2024)

Pharmala Biotech Holdings EV-to-EBIT Chart

Pharmala Biotech Holdings Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
EV-to-EBIT	Get a 7-Day Free Trial						-1.39	-11.58	-27.33	-24.90	-32.32

Competitive Comparison of Pharmala Biotech Holdings's EV-to-EBIT

For the Biotechnology subindustry, Pharmala Biotech Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmala Biotech Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's EV-to-EBIT falls into.

Pharmala Biotech Holdings EV-to-EBIT Calculation

Pharmala Biotech Holdings's EV-to-EBIT for today is calculated as:

Pharmala Biotech Holdings's current Enterprise Value is C$17.20 Mil.
Pharmala Biotech Holdings's EBIT for the trailing twelve months (TTM) ended in Nov. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings  (XCNQ:MDMA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Pharmala Biotech Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Nov. 2023 is calculated as:

Pharmala Biotech Holdings's Enterprise Value for the quarter that ended in Nov. 2023 was C$8.47 Mil.
Pharmala Biotech Holdings's EBIT for the trailing twelve months (TTM) ended in Nov. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings (XCNQ:MDMA) Business Description